Tenet Healthcare is a leading healthcare services company that operates a network of hospitals and healthcare facilities across the United States. The company provides a wide range of medical services, including surgical procedures, emergency care, outpatient services, and specialized treatment programs. Tenet Healthcare focuses on improving patient outcomes and access to care through its integrated care delivery model, collaborating with physicians and health plans to enhance the overall patient experience. In addition to its hospital operations, the company also engages in providing ancillary services, such as laboratory and imaging services, as well as outpatient rehabilitation and urgent care facilities, contributing to a comprehensive approach to healthcare management. Read More
Tenet Healthcare Corporation (NYSE: THC) will release its fourth quarter 2025 results before the market opens on Wednesday, February 11, 2026, to be followed by a conference call at 9:00 a.m. CT (10:00 a.m. Eastern Time).
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Tenet Healthcare (NYSE:THC) and its peers.
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital,
and those that can maintain this trifecta year in and year out often become the legends of the investing world.
As the curtain begins to fall on 2025, the financial landscape presents a stark dichotomy: a "toppy" S&P 500 (INDEXSP: .INX) dominated by artificial intelligence giants and a burgeoning "catch-up" trade in the long-neglected small-cap and value sectors. On December 18, 2025, markets surged following a cooler-than-expected Consumer Price
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Tenet Healthcare (THC) presents a classic value investing case, trading at low valuation multiples while demonstrating strong operational profitability and solid growth prospects.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately -
over the past six months, healthcare stocks have gained 14.1%, nearly mirrorring the S&P 500.
The latest Job Openings and Labor Turnover Survey (JOLTS) data, released on December 9, 2025, for the month of October, presents a nuanced picture of the U.S. labor market. While a slight uptick in job openings might offer a glimmer of resilience, the overarching trends of stagnant hiring and
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
UiPath is deepening its role inside enterprise workflows, and institutional capital is noticing. This breakdown highlights the signals worth tracking as automation enters its next stage.
Shares of hospital operator Tenet Healthcare (NYSE:THC)
jumped 9.7% in the afternoon session after Barclays raised its price target on the company to $240 from $229, signaling continued confidence in the stock.
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Tenet Healthcare (THC) presents a strong value investing case with a low P/E ratio, high profitability, and solid growth outlook, offering a potential margin of safety.
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied.
This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia pulled back after SoftBank sold its stake. This "hurt the AI trade," dragging down related names like Micron and Oracle.
As capital left tech, it sought safety in "higher quality" defensive names. Health care giants like Merck, Amgen, and Johnson & Johnson saw significant buying, boosting the Dow.
Health insurer stocks fell after the Senate ended the shutdown without extending ACA subsidies, delaying the decision to December and raising premium concerns.
Tenet Healthcare’s third quarter results were met with a negative market reaction, despite the company delivering revenue and non-GAAP profit above Wall Street’s expectations. Management highlighted strong performance in both ambulatory surgical centers and hospitals, citing increased same-store growth, high patient acuity, and effective cost controls as key contributors. CEO Saum Sutaria specifically pointed to robust M&A activity and the addition of new facilities, as well as continued improvements in cash collections and operational efficiency. However, investors appeared cautious, reflecting ongoing concerns around operating margins and sector-specific headwinds.
Tenet Healthcare currently trades at $201.39 and has been a dream stock for shareholders. It’s returned 667% since November 2020, blowing past the S&P 500’s 98.9% gain. The company has also beaten the index over the past six months as its stock price is up 35.1% thanks to its solid quarterly results.
Tenet Healthcare Corporation (NYSE: THC) today announced the pricing of the previously announced private placement offering and has agreed to issue and sell $1.5 billion in aggregate principal amount of senior secured first lien notes due on November 15, 2032, which will bear interest at a rate of 5.500% per annum (the “first lien notes”), and $0.75 billion in aggregate principal amount of senior notes due November 15, 2033, which will bear interest at a rate of 6.000% per annum (the “senior notes” and together with the first lien notes, the “notes”). The aggregate principal amount of senior notes to be issued in the offering was increased to $0.75 billion from the previously announced amount of $0.5 billion. Completion of the notes offering is expected to occur on November 18, 2025, and is subject to, among other things, customary closing conditions.
Tenet Healthcare Corporation (NYSE: THC) today announced private placement offerings of $1.5 billion in aggregate principal amount of new senior secured first lien notes due 2032 (the “first lien notes”) and $0.5 billion in aggregate principal amount of new senior notes due 2033 (the “senior notes” and together with the first lien notes, the “notes”) to refinance $2.0 billion of its currently outstanding notes. Completion of the notes offering is subject to, among other things, pricing and customary closing conditions.
